The University of Southampton
University of Southampton Institutional Repository

Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease

Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
Objective: to examine the hepatic effectiveness of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) through a head-to-head comparison with glucagon-like peptide-1 receptor agonists (GLP-1RA) or thiazolidinediones (TZD) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Design: this population-based cohort study was conducted using a nationwide healthcare claims database (2014–2022) of Korea. We included individuals with MASLD (aged ≥40 years) who initiated SGLT-2i or comparator drugs (GLP-1RA or TZD). Primary outcome was a composite of hepatic decompensation events, including ascites, oesophageal varices with bleeding, hepatic failure or liver transplant. Liver-cause death and all-cause death were also assessed as secondary outcomes. Cox proportional hazards models were used to estimated HRs with 95% CIs.

Results: after 1:1 propensity score matching, we included 22 550 patients who initiated SGLT-2i and GLP-1RA (median age=57 years, 60% male), and 191 628 patients who initiated SGLT-2i and TZD (median age=57 years, 72% male). Compared with GLP-1RA, SGLT-2i showed a similar risk of hepatic decompensation events (HR 0.93, 95% CI 0.76 to 1.14). Compared with TZD, SGLT-2i demonstrated a reduced risk of hepatic decompensation events (HR 0.77, 95% CI 0.72 to 0.82). As compared with TZD, the results of secondary analyses showed significantly lower hepatic decompensation event risks with SGLT-2i when stratified by sex (male: HR 0.87 (95% CI 0.80–0.94); female: HR 0.62 (95% CI 0.55–0.69)).

Conclusions: in this nationwide cohort study, SGLT-2i was associated with a lower risk of hepatic decompensation events in patients with MASLD compared with TZD, while demonstrating similar effectiveness to GLP-1RA.


DIABETES MELLITUS, FATTY LIVER
1468-3288
Bea, Sungho
b7b8a11e-6f82-4383-957a-c3223931fd07
Bae, Jae Hyun
6a605c25-af98-437d-949f-1f5a158a44d6
Cho, Young Min
eaef9f52-f90f-41f0-bb7c-12335aaeda37
Chang, Yoosoo
db82bb32-e10a-4c23-9e05-6cddfe994bc9
Ryu, Seungho
ddfbdb4c-9de6-4ee9-8998-99dcd3518928
Byrne, Chrisopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Shin, Ju-Young
19bce74c-2aa9-483a-b6d0-67c91eb9bc9b
Bea, Sungho
b7b8a11e-6f82-4383-957a-c3223931fd07
Bae, Jae Hyun
6a605c25-af98-437d-949f-1f5a158a44d6
Cho, Young Min
eaef9f52-f90f-41f0-bb7c-12335aaeda37
Chang, Yoosoo
db82bb32-e10a-4c23-9e05-6cddfe994bc9
Ryu, Seungho
ddfbdb4c-9de6-4ee9-8998-99dcd3518928
Byrne, Chrisopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Shin, Ju-Young
19bce74c-2aa9-483a-b6d0-67c91eb9bc9b

Bea, Sungho, Bae, Jae Hyun, Cho, Young Min, Chang, Yoosoo, Ryu, Seungho, Byrne, Chrisopher D. and Shin, Ju-Young (2024) Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease. Gut. (doi:10.1136/gutjnl-2024-332687).

Record type: Article

Abstract

Objective: to examine the hepatic effectiveness of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) through a head-to-head comparison with glucagon-like peptide-1 receptor agonists (GLP-1RA) or thiazolidinediones (TZD) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Design: this population-based cohort study was conducted using a nationwide healthcare claims database (2014–2022) of Korea. We included individuals with MASLD (aged ≥40 years) who initiated SGLT-2i or comparator drugs (GLP-1RA or TZD). Primary outcome was a composite of hepatic decompensation events, including ascites, oesophageal varices with bleeding, hepatic failure or liver transplant. Liver-cause death and all-cause death were also assessed as secondary outcomes. Cox proportional hazards models were used to estimated HRs with 95% CIs.

Results: after 1:1 propensity score matching, we included 22 550 patients who initiated SGLT-2i and GLP-1RA (median age=57 years, 60% male), and 191 628 patients who initiated SGLT-2i and TZD (median age=57 years, 72% male). Compared with GLP-1RA, SGLT-2i showed a similar risk of hepatic decompensation events (HR 0.93, 95% CI 0.76 to 1.14). Compared with TZD, SGLT-2i demonstrated a reduced risk of hepatic decompensation events (HR 0.77, 95% CI 0.72 to 0.82). As compared with TZD, the results of secondary analyses showed significantly lower hepatic decompensation event risks with SGLT-2i when stratified by sex (male: HR 0.87 (95% CI 0.80–0.94); female: HR 0.62 (95% CI 0.55–0.69)).

Conclusions: in this nationwide cohort study, SGLT-2i was associated with a lower risk of hepatic decompensation events in patients with MASLD compared with TZD, while demonstrating similar effectiveness to GLP-1RA.


Text
Manuscript_clean - Accepted Manuscript
Download (177kB)
Text
Gut_Figures - Accepted Manuscript
Download (483kB)
Text
gutjnl-2024-332687.full - Version of Record
Download (1MB)

More information

Accepted/In Press date: 21 August 2024
e-pub ahead of print date: 6 September 2024
Published date: 6 September 2024
Additional Information: Publisher Copyright: © Author(s) (or their employer(s)) 2024.
Keywords: DIABETES MELLITUS, FATTY LIVER

Identifiers

Local EPrints ID: 493815
URI: http://eprints.soton.ac.uk/id/eprint/493815
ISSN: 1468-3288
PURE UUID: dc35ca80-de30-4ca5-a3f8-1a437d243b10
ORCID for Chrisopher D. Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 13 Sep 2024 16:34
Last modified: 23 Nov 2024 02:37

Export record

Altmetrics

Contributors

Author: Sungho Bea
Author: Jae Hyun Bae
Author: Young Min Cho
Author: Yoosoo Chang
Author: Seungho Ryu
Author: Ju-Young Shin

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×